| Title: |
Impact of pre-biologic impairment on meeting domain-specific biologic responder definitions in patients with severe asthma. |
| Authors: |
Perez-de-Llano, L; Scelo, G; Canonica, GW; Chen, W; Henley, W; Larenas-Linnemann, D; Peters, MJ; Pfeffer, PE; Tran, TN; Ulrik, CS; Popov, TA; Sadatsafavi, M; Hew, M; Máspero, J; Gibson, PG; Christoff, GC; Fitzgerald, JM; Torres-Duque, CA; Porsbjerg, CM; Papadopoulos, NG; Papaioannou, AI; Heffler, E; Iwanaga, T; Al-Ahmad, M; Kuna, P; Fonseca, JA; Al-Lehebi, R; Rhee, CK; Koh, MS; Cosio, BG; Perng Steve, D-W; Mahboub, B; Menzies-Gow, AN; Jackson, DJ; Busby, J; Heaney, LG; Patel, PH; Wang, E; Wechsler, ME; Altraja, A; Lehtimäki, L; Bourdin, A; Bjermer, L; Bulathsinhala, L; Carter, V; Murray, R; Beastall, A; Denton, E; Price, DB |
| Publication Year: |
2023 |
| Collection: |
Queen Mary University of London: Queen Mary Research Online (QMRO) |
| Description: |
BACKGROUND: There is little agreement on clinically useful criteria for identifying real-world responders to biologic treatments for asthma. OBJECTIVE: To investigate the impact of pre-biologic impairment on meeting domain-specific biologic responder definitions in adults with severe asthma. METHODS: This was a longitudinal, cohort study across 22 countries participating in the International Severe Asthma Registry (https://isaregistries.org/) between May 2017 and January 2023. Change in 4 asthma domains (exacerbation rate, asthma control, long-term oral corticosteroid [LTOCS] dose, and lung function) was assessed from biologic initiation to 1 year post-treatment (minimum 24 weeks). Pre- to post-biologic changes for responders and nonresponders were described along a categorical gradient for each domain derived from pre-biologic distributions (exacerbation rate: 0 to 6+/y; asthma control: well controlled to uncontrolled; LTOCS: 0 to >30 mg/d; percent-predicted forced expiratory volume in 1 second [ppFEV1]: |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| Relation: |
Ann Allergy Asthma Immunol; https://qmro.qmul.ac.uk/xmlui/handle/123456789/94053 |
| DOI: |
10.1016/j.anai.2023.12.023 |
| Availability: |
https://qmro.qmul.ac.uk/xmlui/handle/123456789/94053; https://doi.org/10.1016/j.anai.2023.12.023 |
| Rights: |
Attribution 3.0 United States ; http://creativecommons.org/licenses/by/3.0/us/ ; © 2024 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. |
| Accession Number: |
edsbas.D3D7D976 |
| Database: |
BASE |